RE: .10 Mar 2020 14:50
Extrapolating isn't an issue at all IMO considering the upward increase in cases demand is likely to be higher as time passes by... then you have to consider re-infection, new strains etc etc
P/E is a little trickier, due to the nature of event, but still a matter of fact - if trading updates are solid people will apply ratios to it
Approvals and contracts have always been key as it provides validation of product, still too many unknowns at this stage though
IMO